HANFA has established that since 29 June when it acquired 1,505,943 ordinary shares (in Pliva) and 371,865 GDRs, and that on the basis of concluded optional contracts, Actavis has been controlling 20.4 percent of Pliva's shares.
Quoting relevant Croatian laws, HANFA recalled on Monday that Actavis was bound to publish its intent to issue an offer for the acquisition of Pliva.
In light of the fact that Actavis failed to do it until Monday, HANFA issued the directive ordering Actavis to publish its intent, the Croatian regulatory body said in a press release.
The US Company Barr Pharmaceuticals, the other company which is in the bidding war for Pliva, earlier on Monday published its intent to issue an offer for the takeover of the Croatian generic drug maker Pliva, stressing that it will issue its takeover offer within the legally stipulated deadline.